|
1) Ladhams A, Schmidt C, Sing G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol. 2002; 17: 889-96
|
|
|
|
2) Iwashita Y, Tahara K, Goto S, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother. 2003; 52: 155-61
|
|
|
|
|
|
3) Nakamoto Y, Mizukoshi E, Tsuji H, et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol. 2007; 147: 296-305
|
|
|
|
|
|
4) Nakamoto Y, Mizukoshi E, Kitahara M, et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol. 2011; 163: 165-77
|
|
|
|
|
|
5) Zhou P, Liang P, Dong B, et al. Phase I clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol Ther. 2011; 11: 450-6
|
|
|
|
|
|
6) Hu CE, Gan J, Zhang RD, et al. Up-regulation of myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol. 2011; 46: 156-64
|
|
|
|
|
|
7) Iida N, Nakamoto Y, Baba Y, et al. Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC chemokine ligand 3/macrophage inflammatory protein-1α. Cancer Res. 2010; 70: 6556-65
|
|
|
|
|
|
8) Cabillic F, Toutirais O, Lavoue V, et al. Aminobisphosphonate-pretreated dendritic cells trigger successful Vγ9Vδ2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol Immunother. 2010; 59: 1611-9
|
|
|
|
|
|
9) Sun JC, Pan K, Chen MS, et al. Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. Cancer Biol Ther. 2010; 10: 368-75
|
|
|
|
|
|
10) Mizukoshi E, Nakamoto Y, Tsuji H, et al. Identification of α-fetoprotein-derived peptides recognized by cytooxic T lymphocytes in HLA-A24＋ patients with hepatocellular carcinoma. Int J Cancer. 2006; 118: 1194-204
|
|
|
|
|
|
11) Butterfield LH, Ribas A, Meng WS, et al. T-cell responses to HLA-A＊ 0201 immunodominant peptides derived from a-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003; 9: 5902-8
|
|
|
|
|
|
12) Bricard G, Bouzourene H, Martinet O, et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8＋ T cell responses in patients with hepatocellular carcinoma. J Immunol. 2005; 174: 1709-16
|
|
|
|
|
|
13) Shang XY, Chen HS, Zhang HG, et al. The spontaneous CD8＋ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res. 2004; 10: 6946-55
|
|
|
|
|
|
14) Zhang HG, Chen HS, Peng JR, et al. Specific CD8(＋) T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol Immunother. 2007; 56: 1945-54
|
|
|
|
|
|
15) Komori H, Nakatsura T, Senju S, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006; 12: 2689-97
|
|
|
|
|
|
16) Motomura Y, Ikuta Y, Kuronuma T, et al. HLA-A2 and A24-restricted glypican-3 derived peptide vaccine specific CTLs: preclinical study using mice. Int J Oncol. 2008; 32: 985-90
|
|
|
|
|
|
17) Behboudi S, Alisa A, Boswell S, et al. Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stage of disease. Br J cancer. 2010; 102: 748-53
|
|
|
|
|
|
18) Yoshikawa T, Nakatsugawa M, Suzuki S, et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci. 2011; 102: 918-25
|
|
|
|
|
19) Greten TF, Forner A, Korangy F, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010; 10: 209
|
|
|
|
|
|
20) Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 2002; 94: 435-42
|
|
|
|
|
|
21) Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type I interferon receptor expression. Br J Cancer. 2005; 93: 557-64
|
|
|
|
|
|
22) Obi S, Yoshida H, Toune R, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006; 106: 1990-7
|
|
|
|
|
|
23) Mawatari H, Kirikoshi H, Yoneda M, et al. Effective treatment of advanced hepatocellular carcinoma with portal venous invasion using a combination therapy of intra-arterial 5-fuluorourasil and subcutaneous pegylated-interferon-α2b. Hepatogastroenterology. 2008; 55: 1776-7
|
|
|
|
|
|
24) Ueshima K, Kudo M, Nagai T, et al. Combination therapy with S-1 and pegylated interferonα for advanced hepatocellular carcinoma. Oncology. 2008; 75(supple1): 106-13
|
|
|
|
|
|
25) Hu P, Hu HD, Chen M, et al. Expression of interleukin-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol Immunol. 2009; 48: 1654-62
|
|
|
|
|
|
26) Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patinets with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316: 889-97
|
|
|
|
|
|
27) Hui D, Qiang L, Jain W, et al, A randomized controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 2009; 41: 36-41
|
|
|
|
|
|
28) Cany J, Tran L, Gauttier V, et al. Immunotherapy of hepatocellular carcinoma: is there a place for regulatory T-lymphocyte depletion？ Immunotherapy. 2011; 3: 32-4
|
|
|
|
|
|
29) Mizukoshi E, Nakamoto Y, Arai K, et al. Comparative analysis of various tumor-associated antigen-specific T cell responses in patients with hepatocellular carcinoma. Hepatology. 2011; 53: 1206-16
|
|
|
|
|
|
30) Greten TF, Ormandy LA, Fikuart A, et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4＋ T-cell responses in patients with advanced HCC. J Immunother. 2010; 33: 211-8
|
|
|
|
|
|
31) Hoechst B, Voigtlaender T, Ormandy L, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocelluar carcinoma via NKp30 receptor. Hepatology. 2009; 50: 799-807
|
|
|
|
|
|
32) Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in human liver. Immunol Rev. 2000; 174: 5-20
|
|
|
|
|
|
33) Nobuoka D, Kato Y, Gotohda N, et al. Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep. 2010; 24: 521-8
|
|
|
|
|
|
34) Yamamoto M, Tatsumi T, Miyagi T, et al. α-fetoprotein impairs activation of NK cells by inhibiting the function of dendritic cells. Clin Exp Immunol. 2011; 165: 211-9
|
|
|
|
|
|
35) Kohga K, Takehara T, Tatsumi T, et al. Serum levels of major histocompatibility complex (MHC) class I-related chain A in patients with chronic diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci. 2008; 99: 1643-9
|
|
|
|
|
|
36) Kohga K, Takehara T, Tatsumi T, et al. Anti-cancer chemotherapy inhibits MICA ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res. 2009; 69: 8050-7
|
|
|
|
|
|
37) Kohga K, Takehara T, Tatsumi T, et al. Sorafenib inhibits the shedding of MICA on hepatocellular cacrcinoma cell by downregulating ADAM9. Hepatology. 2010; 51: 1264-73
|
|
|
|
|
|
38) Kohga K, Tatsumi T, Takehara T, et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol. 2010; 52: 872-9
|
|
|
|
|